Literature DB >> 12880282

Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates.

Sébastien A Gittens1, John R Matyas, Ronald F Zernicke, Hasan Uludağ.   

Abstract

PURPOSE: To develop a novel means of conjugating bisphosphonates onto the carbohydrate moieties of glycoproteins to enhance protein affinity to bone.
METHODS: 1-Amino-1,1-diphosphonate methane (aminoBP) was conjugated onto the carbohydrate moietites of oxidized fetuin by using 4-(maleimidomethyl)cyclohexane-1-carboxyl-hydrazide (MMCCH). Bone affinity of the resulting conjugates was compared to proteins obtained from another means of conjugation, whereby aminoBP was conjugated onto fetuin's lysine moieties by using succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC).
RESULTS: The use of the MMCCH resulted in the conjugation of up to seven aminoBPs per molecule of fetuin. These conjugates gave a 2.6-, 2.0-, 30.5-. and 1.84-fold increased affinity for untreated, ashed, demineralized bone and hydroxyapatite, respectively, as compared to conjugates from the SMCC reaction. Both conjugates exhibited a pH-independent, equally slow degradation in adult bovine serum-containing media.
CONCLUSION: The use of the MMCCH chemistry to conjugate aminoBP onto fetuin was feasible. Furthermore, the described processes of conjugation resulted in amino-BP-dependent increase in the glycoprotein's affinity to various bone matrices in a manner that exceeds the affinity produced by the previously established method, which used SMCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880282     DOI: 10.1023/a:1024445903306

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

1.  Clearance properties of liposomes involving conjugated proteins for targeting.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-06-08       Impact factor: 15.470

2.  Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells.

Authors:  S F Atkinson; T Bettinger; L W Seymour; J P Behr; C M Ward
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

3.  Bone induction by Escherichia coli -derived recombinant human bone morphogenetic protein-2 compared with Chinese hamster ovary cell-derived recombinant human bone morphogenetic protein-2.

Authors:  K Bessho; Y Konishi; S Kaihara; K Fujimura; Y Okubo; T Iizuka
Journal:  Br J Oral Maxillofac Surg       Date:  2000-12       Impact factor: 1.651

4.  PERIODATE OXIDATION OF THE GLYCOPROTEIN FETUIN.

Authors:  R G SPIRO
Journal:  J Biol Chem       Date:  1964-02       Impact factor: 5.157

5.  alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling.

Authors:  Melanie Szweras; Danmei Liu; Emily A Partridge; Judy Pawling; Balram Sukhu; Cameron Clokie; Willi Jahnen-Dechent; Howard C Tenenbaum; Carol J Swallow; Marc D Grynpas; James W Dennis
Journal:  J Biol Chem       Date:  2002-03-18       Impact factor: 5.157

6.  Preparative two-step purification of recombinant human basic fibroblast growth factor from high-cell-density cultivation of Escherichia coli.

Authors:  G Garke; W D Deckwer; F B Anspach
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-01-14

7.  Micro method for determination of reactive carbonyl groups in proteins and peptides, using 2,4-dinitrophenylhydrazine.

Authors:  R Fields; H B Dixon
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

8.  Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.

Authors:  Keith Thompson; James E Dunford; Frank H Ebetino; Michael J Rogers
Journal:  Biochem Biophys Res Commun       Date:  2002-01-18       Impact factor: 3.575

9.  Bisphosphonate conjugation to proteins as a means to impart bone affinity.

Authors:  H Uludag; N Kousinioris; T Gao; D Kantoci
Journal:  Biotechnol Prog       Date:  2000 Mar-Apr

10.  Surface engineering of living myoblasts via selective periodate oxidation.

Authors:  P A De Bank; B Kellam; D A Kendall; K M Shakesheff
Journal:  Biotechnol Bioeng       Date:  2003-03-30       Impact factor: 4.530

View more
  3 in total

1.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

2.  Impact of tether length on bone mineral affinity of protein-bisphosphonate conjugates.

Authors:  Sébastien A Gittens; Pavel I Kitov; John R Matyas; Raimar Löbenberg; Hasan Uludağ
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

3.  Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface.

Authors:  Robin S Ehrick; Marcello Capaccio; David A Puleo; Leonidas G Bachas
Journal:  Bioconjug Chem       Date:  2007-11-15       Impact factor: 4.774

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.